Jun 21, 2021 7:00am EDT Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)
Jun 16, 2021 7:00am EDT Tonix Pharmaceuticals to Present at Raymond James Human Health Innovation Conference
Jun 3, 2021 7:00am EDT Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 26, 2021 7:00am EDT Tonix Pharmaceuticals Announces Presentation of Two Posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 10, 2021 4:30pm EDT Tonix Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
Apr 21, 2021 7:00am EDT Tonix Pharmaceuticals to Participate in Fourth Annual Neuroscience Innovation Forum
